Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Current therapy for asthma
Autore:
Barnes, PJ;
Indirizzi:
Natl Heart & Lung Inst, Dept Thorac Med, Imperial Coll, London SW3 6LY, England Natl Heart & Lung Inst London England SW3 6LY l, London SW3 6LY, England
Titolo Testata:
NEW DRUGS FOR ASTHMA, ALLERGY AND COPD
, volume: 31, anno: 2001,
pagine: 6 - 10
SICI:
1422-2140(2001)31:<6:CTFA>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
DRUG-THERAPY; INHALED CORTICOSTEROIDS; MILD ASTHMA; THEOPHYLLINE; BUDESONIDE; SALMETEROL; IMMUNOTHERAPY; MANAGEMENT;
Tipo documento:
Article
Natura:
Collana
Settore Disciplinare:
Clinical Medicine
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Barnes, PJ Natl Heart & Lung Inst, Dept Thorac Med, Imperial Coll, Dovehouse St, London SW3 6LY, England Natl Heart & Lung Inst Dovehouse St London England SW3 6LY and
Citazione:
P.J. Barnes, "Current therapy for asthma", PROG R RES, 31, 2001, pp. 6-10

Abstract

Currently available therapy for asthma is highly effective and is able to control the majority of patients so that they can lead a normal life. National and international guidelines for the treatment of asthma are generally based on use of inhaled beta (2)-agonists together with inhaled corticosteroids. Advances in therapy have been due to the introduction of more effective and safer treatments and to changes in the way that these treatments areadministered to patients. This represented an important change in strategyfrom the treatment of symptoms as they arose largely with bronchodilator therapy to control and prevent symptoms with anti-inflammatory treatments. The earlier and more widespread use of inhaled corticosteroids has revolutionized asthma therapy over the last 10 years, with improvement in asthma control, a reduction in asthma morbidity and almost certainly a decrease in mortality [1]. In most countries, guidelines for asthma therapy have now been introduced and these form the framework of modem management, with a stepwise escalation in therapy [2, 3]. Asthma therapies are now classified as relievers that provide rapid relief of symptoms (short-acting beta (2)-agonists, anticholinergics) that are used as needed and controllers which provide long-term control of symptoms that are used as a regular treatment (corticosteroids, theophylline, long-acting inhaled beta (2)-agonists, cromones, anti-leukotrienes and immunomodulators) (table 1).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 19:03:17